IMMUNOGLOBULIN estimations at diagnosis have been reported in only one large series of children with acute lymphoblastic leukaemia (ALL) (Khalifa et al., 1974) . We therefore looked at the initial Ig levels in a large unselected series of children with ALL presenting to the Royal Manchester Children's Hospital Regional Paediatric Oncology Unit between 1971 and An attempt was made to relate the levels to prognosis, clinical features and response to treatment.
196 consecutive children were investigated before starting treatment. Diagnosis of ALL was made as described by Hayhoe et al. (1964) . All samples were collected before any blood transfusion was given, stored at -20°C and tested within a week. IgG, IgA and IgM levels were measured using immunodiffusion plates (Hoechst). Low levels of IgA were checked using "low level" plates. Low IgGs were repeated with a less diluted serum. The precision of the assays was 6.6%, 5.8% and 5*6% (coefficient of variation, n= Table) . None of these children with low Igs had proteinuria, and all had normal blood-albumin levels. The Philadelphia chromosome was not demonstrated in any of the low-immunoglobulin group.
The length of first remission was plotted using the life-table method (Fig.) and differences were analysed for significance using the logrank tests of Peto et al. (1977) . There was no significant difference between patients with normal and raised Ig. There was, however, a significant deleterious effect of low Ig on remission duration (P = 0-01) which was retained even after simultaneous adjustment by the regression method of Cox (1972) for the effects of other known prognostic features (i.e. total white-cell count, immunological surface markers, age, mediastinal mass and degree of hepatosplenomegaly).
Studies by Freireich et al. (1975) and Hersh et al. (1971) Cornbleet & Chessells (1978) .
Membrane surface markers were not available when 6 of our patients presented. Of the other 4, 1 had a B-cell leukaemia, and the other 3 were of the non-B, non-T type. Three patients had an initial whitecell count over 20 x 109/1, a feature which may be associated with leukaemia of Tcell origin, but no patient had an anterior mediastinal mass. The group is too small for comment on susceptibility to infection, which might be expected to be enhanced, but the one patient who has otherwise done well (Patient 1) had an episode of salmonella septicaemia with subsequent prolonged faecal excretion.
The outstanding feature was the very poor response to treatment, for both induction of remission and re-induction after relapse. Only 1 case (with low initial IgG) responded well. The median lengths of first remission (8 months) and of survival (17k months) are also poor. Only 3 of the 10 patients are still alive. All but Patient 1 have relapsed, although 5 had what are considered better risk features (i.e. lack of mediastinal mass, initial white-cell count less than 20 x 109/1 and age below 12 years). Two patients (Nos. 2 and 4) needed prolonged treatment before a first remission was induced. Second remissions in 9 of the children were very difficult to achieve. The patient with B-cell leukaemia did not achieve a remission, a feature which has been well described in this type of disease by Freireich et al. (1975) and others.
Recent reports from Broder et al. (1977 Broder et al. ( , 1978 have shown that some patients with leukaemia of T-cell origin have hypogammaglobulinaemia because the blast cells have suppressor-cell activity. Helper cells have been described in some of Broder's patients with Sezary's syndrome, and both helper and suppressor cells in a T-cell-derived chronic lymphocytic leukaemia patient of Saxon et al. (1979) . Such findings indicate that neoplastic cells can retain normal function, and may thus provide a valuable supply of human helper and suppressor cells for research. Their characterization may also define patients with acute leukaemia who have exceptionally poor anti-tumour and anti-microbial defences. It would also appear that patients with B-cell and non-B-, non-T (common) ALL may also have a low Ig level which is related to a particularly poor prognosis, and outweighs other factors which would otherwise indicate a good risk. Consequently, identification of patients with low IgA or IgG will allow more accurate stratification of trials for analysis and make possible the selection of these patients for non-conventional intensive treatments such as marrow transplantation.
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